Cerus Corporation (CERS): Price and Financial Metrics


Cerus Corporation (CERS): $3.98

-0.17 (-4.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CERS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CERS POWR Grades

  • Sentiment is the dimension where CERS ranks best; there it ranks ahead of 86.49% of US stocks.
  • CERS's strongest trending metric is Value; it's been moving up over the last 178 days.
  • CERS ranks lowest in Momentum; there it ranks in the 10th percentile.

CERS Stock Summary

  • CERUS CORP's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 79.48% of US listed stocks.
  • Over the past twelve months, CERS has reported earnings growth of -40.62%, putting it ahead of 25.85% of US stocks in our set.
  • Revenue growth over the past 12 months for CERUS CORP comes in at 30.81%, a number that bests 73.11% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CERUS CORP are VLD, VNRX, BLI, IPWR, and VRAR.
  • CERS's SEC filings can be seen here. And to visit CERUS CORP's official web site, go to www.cerus.com.

CERS Valuation Summary

  • In comparison to the median Healthcare stock, CERS's price/sales ratio is 95% higher, now standing at 3.9.
  • Over the past 243 months, CERS's price/sales ratio has gone down 40.6.

Below are key valuation metrics over time for CERS.

Stock Date P/S P/B P/E EV/EBIT
CERS 2022-12-02 3.9 10.1 -19.2 -24.4
CERS 2022-12-01 3.9 10.0 -19.1 -24.3
CERS 2022-11-30 3.8 9.7 -18.5 -23.6
CERS 2022-11-29 3.5 8.9 -16.9 -21.7
CERS 2022-11-28 3.5 9.0 -17.2 -21.9
CERS 2022-11-25 3.7 9.4 -17.9 -22.8

CERS Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 27.26%.
  • Its 3 year price growth rate is now at -26.94%.
  • Its 3 year net income to common stockholders growth rate is now at 21.24%.
CERS's revenue has moved up $118,896,000 over the prior 52 months.

The table below shows CERS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 187.082 -25.081 -38.274
2022-06-30 182.84 -29.605 -42.229
2022-03-31 172.972 -37.402 -49.201
2021-12-31 159.518 -33.922 -54.374
2021-09-30 143.02 -41.158 -59.636
2021-06-30 130.11 -39.255 -61.338

CERS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CERS has a Quality Grade of C, ranking ahead of 39.02% of graded US stocks.
  • CERS's asset turnover comes in at 0.647 -- ranking 61st of 186 Medical Equipment stocks.
  • BSGM, NVCR, and STRR are the stocks whose asset turnover ratios are most correlated with CERS.

The table below shows CERS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.647 0.607 -0.310
2021-06-30 0.592 0.619 -0.303
2021-03-31 0.547 0.631 -0.294
2020-12-31 0.528 0.640 -0.286
2020-09-30 0.529 0.643 -0.318
2020-06-30 0.530 0.654 -0.360

CERS Price Target

For more insight on analysts targets of CERS, see our CERS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.00 Average Broker Recommendation 1.2 (Strong Buy)

CERS Stock Price Chart Interactive Chart >

Price chart for CERS

CERS Price/Volume Stats

Current price $3.98 52-week high $7.20
Prev. close $4.15 52-week low $3.25
Day low $3.97 Volume 766,479
Day high $4.19 Avg. volume 1,642,837
50-day MA $3.71 Dividend yield N/A
200-day MA $4.72 Market Cap 706.14M

Cerus Corporation (CERS) Company Bio


Cerus Corporation operates as a biomedical products company which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company was founded in 1991 and is based in Concord, California.


CERS Latest News Stream


Event/Time News Detail
Loading, please wait...

CERS Latest Social Stream


Loading social stream, please wait...

View Full CERS Social Stream

Latest CERS News From Around the Web

Below are the latest news stories about CERUS CORP that investors may wish to consider to help them evaluate CERS as an investment opportunity.

Cerus Third Quarter 2022 Earnings: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021)

Cerus ( NASDAQ:CERS ) Third Quarter 2022 Results Key Financial Results Revenue: US$39.6m (up 9.5% from 3Q 2021). Net...

Yahoo | November 9, 2022

Cerus Corporation to Participate in Upcoming Investor Conferences

CONCORD, Calif., November 04, 2022--Cerus Corporation (Nasdaq: CERS) announced today that Vivek Jayaraman, Cerus’ chief operating officer, is scheduled to participate in two conferences:

Yahoo | November 4, 2022

Cerus (CERS) Reports Q3 Loss, Tops Revenue Estimates

Cerus (CERS) delivered earnings and revenue surprises of 0% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Cerus Corporation Announces Third Quarter Financial Results

CONCORD, Calif., November 03, 2022--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2022.

Yahoo | November 3, 2022

Cerus Corporation Announces Award of U.S. Department of Defense Funding for Development of Pathogen Reduced, Lyophilized Cryoprecipitate

CONCORD, Calif., November 02, 2022--Cerus Corporation (Nasdaq: CERS) today announced that it has been awarded a $9.1 million contract by the U.S. Department of Defense (DoD) Industrial Base Analysis and Sustainment (IBAS) program for the development of pathogen reduced, lyophilized cryoprecipitate ("LyoCryo") to treat bleeding due to trauma.

Yahoo | November 2, 2022

Read More 'CERS' Stories Here

CERS Price Returns

1-mo 5.85%
3-mo 1.27%
6-mo -24.91%
1-year -40.06%
3-year -2.69%
5-year 10.25%
YTD -41.56%
2021 -1.59%
2020 63.98%
2019 -16.77%
2018 50.00%
2017 -22.30%

Continue Researching CERS

Want to see what other sources are saying about Cerus Corp's financials and stock price? Try the links below:

Cerus Corp (CERS) Stock Price | Nasdaq
Cerus Corp (CERS) Stock Quote, History and News - Yahoo Finance
Cerus Corp (CERS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7548 seconds.